Dr. Kim Papp
Dr. Kim Papp is a Member of the College of Physicians and Surgeons of Ontario, a Fellow of the Royal College of Physicians and Surgeons of Canada, and a Fellow of the American Academy of Dermatology. He has over 25 years’ experience as a Principal Investigator and has conducted numerous studies in psoriasis and other indications.
Dr. Papp, with the support of Probity Medical Research, an organization for which he is Founder and President, has become one of the world’s leading experts in the treatment of psoriasis and atopic dermatitis.
Dr. Papp has acted as a consultant and/or advisor for over 50 pharmaceutical and biotech companies.
Dr. Papp is an author on over 500 publications. His current academic interests include the assessment of disease severity measures, the impact of bias and error on disease severity measures and clinical trial results, clinical trial design, and the development of meaningful clinical guidelines and treatment targets. In addition, Dr. Papp maintains a general Dermatology practice in Waterloo, Ontario, Canada.
SAT Apr 29
Make It PsO: The Next Generation of Topical Treatments
Objectives of the session:
- Discuss unmet needs for topical treatments in the management of the chronic disease plaque psoriasis (PsO) from patients’ and physicians’ perspectives.
- Review the benefits and challenges of current plaque PsO topical treatment approaches.
- Examine next generation topical formulation considerations for the practical management of chronic plaque PsO.
Summary description of the session:
Join us for the second episode of PsO Let’s Talk with our expert guest host, Dr. Perla Lansang. For the past 60 years, topical therapies remain the foundation of chronic plaque PsO treatment, yet many unmet needs still exist. A novel non-steroidal topical treatment option has not been approved in Canada for over 20 years. Plaque PsO is a heterogenous and chronic disease, with almost 90% of patients experiencing PsO in more than one location with a median disease duration of 50 years; however, no one topical therapy safely addresses all affected areas and there are growing concerns, real and perceived, from patients as steroid-phobia continues to gain presence in many social media outlets. Dermatologists often need to prescribe PsO patients a complex regimen consisting of at least 2-3 different topicals of varying potencies, of which many may have treatment limitations due to adverse events compromising their acceptance by patients for chronic use. Additionally, despite the many currently available topical treatments, patients with plaque PsO still experience the highly disruptive symptom of itch that negatively affects their quality of life.
This open session will discuss current and new developments in topical treatment for chronic plaque PsO by examining efficacy, safety/tolerability, and vehicle formulation considerations towards the clinical goal for a simplified regimen. The expert speaker panel from the final frontier, Dr. Kim ‘Papp-card’ and Dr. ‘Bones’ Turchin, will ‘Make It PsO’ the audience gains a better understanding of the ongoing challenges in the management of this chronic auto-immune inflammatory skin condition, and how this next generation of topical non-steroidal therapy may address these unmet needs.
SAT Apr 29
Arcutis Canada National Dermatology Advisory